- $90.92bn
- $114.89bn
- $247.12bn
- 94
- 66
- 62
- 88
Annual income statement for Cigna, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 160,197 | 174,069 | 180,518 | 195,265 | 247,121 |
Cost of Revenue | |||||
Gross Profit | 24,003 | 22,951 | 23,500 | 25,177 | 25,964 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 148,040 | 166,269 | 170,406 | 188,228 | 237,862 |
Operating Profit | 12,157 | 7,800 | 10,112 | 7,037 | 9,259 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 10,868 | 6,790 | 8,397 | 5,513 | 5,269 |
Provision for Income Taxes | |||||
Net Income After Taxes | 8,489 | 5,420 | 6,782 | 5,372 | 3,778 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 8,458 | 5,370 | 6,704 | 5,164 | 3,434 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 8,458 | 5,370 | 6,704 | 5,164 | 3,434 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 10.5 | 16.6 | 17.5 | 28.3 | 13.7 |
Dividends per Share |